BioAge Labs Inc

BioAge Labs reports 2025 results, raises $132M, and shares Phase‑1 successes for BGE‑102, a promising NLRP3 anti‑inflammatory therapy targeting aging‑related diseases.

BioAge Labs, a clinical-stage biopharmaceutical company, has reported its second quarter 2025 financial results, highlighting its progress in developing therapeutic solutions for metabolic diseases, including its lead product BGE-102.